Effect of Majoon Najjah in perimenopausal depression - An open Labelled study

Kouser Fathima Firdose0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•1. Females who are currently physically well and between 40 and 65 years of age
•2. Current DSM-IV diagnosis of depression disorder
•3. Able to give informed consent
•4. Perimenopausal as determined by symptom profile on the Stages of Reproductive Aging Workshop and gonadal hormonal profile

•1. Known abnormalities in the hypothalamic-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event, breast pathology, undiagnosed vaginal bleeding or abnormal Pap smear results in the previous 2 years.
•2. Patients with H/O any significant unstable medical illness such as epilepsy and diabetes, hypertension or known active cardiac, renal or liver disease;malignancy or the presence of illness causing immobilisation.
•3. Patients receiving treatment for depression including antidepressant medications, electroconvulsive therapy (ECT) / Transcranial Magnetic Stimulation (TMS), formal psychotherapy or counselling, within the past 6 months.
•4. Patients experiencing severe melancholia, neurovegetative symptoms or current suicidality necessitating acute hospitalisation or intensive psychiatric treatment.
•5. Patients with psychotic symptoms or past history of severe mental illness including schizophrenia, and bipolar disorder.
•6. Use of any form of estrogen, progestin or androgen as hormonal therapy, or antiandrogen including tibolone or use of phytoestrogen supplements as powder or tablet.

发起方

Kouser Fathima Firdose